key: cord-0858657-hp8gj4z8
authors: Herrera, Emilio A.; Gonzalez-Candia, Alejandro
title: Comment on Melatonin as a potential adjuvant treatment for COVID-19
date: 2020-04-30
journal: Life Sci
DOI: 10.1016/j.lfs.2020.117739
sha: 6f408c9f7fc9d9acd53b32cc6f9b01406b797f55
doc_id: 858657
cord_uid: hp8gj4z8

nan

J o u r n a l P r e -p r o o f associated with increased nitric oxide -dependent and -independent vasodilator functions. Interestingly, one of the nitric oxide independent affected mechanisms, was the enhanced expression of the prostacyclin vasodilator pathway [3, 4] . The aforementioned findings were also associated with increased expression and/or activity of the endogenous antioxidant enzymes, superoxide dismutase and catalase, an enhanced plasma antioxidant capacity and a marked decreased in pulmonary oxidative stress markers [2, 3] .

Furthermore, these effects were associated with a diminished vascular remodeling of the pulmonary circulation after 1 week of treatment [5] .

The vasodilatory effects of melatonin are in part a consequence of the antioxidant and anti-inflammatory effects that reverberates on an improved vascular structure and function, but as well they can be due to its direct effects as a vasodilator (Fig.1, unpublished data) . Although it gives a mild ex vivo vasodilation, the global in vivo effects of melatonin offer a better pulmonary function.

Melatonin pulmonary effects have also been tested in adult animals. For [6] demonstrated that melatonin improved right ventricular function and reduced cardiac remodeling in pulmonary hypertensive (PAH) rats, suggesting a pressure decrease in the pulmonary artery. In addition, melatonin has been tested in rats with chronic obstructive pulmonary disease [7] , where it attenuated pulmonary hypertension by antagonizing the oxidative injury and restore nitric oxide production. Moreover, the anti-inflammatory effects of melatonin restore vascular homeostasis in PAH mice and improve endothelial integrity [8] . Finally, the direct vasodilator effects of melatonin in pulmonary arteries and vein on adult animals (sheep) has also been reported [9] .

Although there are no studies that evaluate the vasoactive properties of melatonin in humans, the evidence of its beneficial effects in animals is convincing.

COVID-19: Melatonin as a potential adjuvant treatment

Melatonin reduces oxidative stress and improves vascular function in pulmonary hypertensive newborn sheep

Melatonin long-lasting beneficial effects on pulmonary vascular reactivity and redox balance in chronic hypoxic ovine neonates

Melatonin Decreases Pulmonary Vascular Remodeling and Oxygen Sensitivity in Pulmonary Hypertensive Newborn Lambs

Melatonin as a preventive and curative therapy against pulmonary hypertension

Melatonin Attenuates Pulmonary Hypertension in Chronically Hypoxic Rats

Melatonin inhibits inflammasome-associated activation of endothelium and macrophages attenuating pulmonary arterial hypertension

Effects of melatonin on isolated pulmonary artery and vein: role of the vascular endothelium

Rationale for Their Utilization as Adjunctive Countermeasures in the Treatment of Coronavirus Disease 2019 (COVID-19)